|
|
Article: Neupro(R) Filed with the FDA for the Treatment of Restless Legs Syndrome.
- Article from:
- PR Newswire
- Article date:
- December 13, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The U.S. Food and Drug Administration (FDA) has accepted for filing the Supplemental New Drug Application (sNDA) for the use of Neupro(R) (Rotigotine Transdermal System) as a treatment for moderate-to-severe restless legs syndrome (RLS)
ATLANTA, Dec. 13 /PRNewswire/ -- UCB announced today that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as a treatment for moderate-to-severe restless legs syndrome (RLS) has been accepted for filing by the U.S. Food and Drug Administration (FDA). Neupro(R) is a patch designed to provide continuous drug delivery. Restless legs syndrome is a chronic neurological disorder that affects between three and ten ...